Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

Virtual Booth

Contact Supplier

Bora Pharmaceuticals- Making success more certain.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

3DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 932372-01-5, Asapiprant [inn], Bge-175, B2lw71crgl, S-555739, Bge175

Molecular Formula

C₂₄H₂₇N₃O₇S

Molecular Weight

501.6 g/mol

InChI Key

ZMZNWNTZRWXTJU-UHFFFAOYSA-N

FDA UNII

B2LW71CRGL

1 2D Structure

Asapiprant

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-[2-(1,3-oxazol-2-yl)-5-[4-(4-propan-2-yloxyphenyl)sulfonylpiperazin-1-yl]phenoxy]acetic acid

2.1.2 InChI

InChI=1S/C24H27N3O7S/c1-17(2)34-19-4-6-20(7-5-19)35(30,31)27-12-10-26(11-13-27)18-3-8-21(24-25-9-14-32-24)22(15-18)33-16-23(28)29/h3-9,14-15,17H,10-13,16H2,1-2H3,(H,28,29)

2.1.3 InChI Key

ZMZNWNTZRWXTJU-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C)OC1=CC=C(C=C1)S(=O)(=O)N2CCN(CC2)C3=CC(=C(C=C3)C4=NC=CO4)OCC(=O)O

2.2 Other Identifiers

2.2.1 UNII

B2LW71CRGL

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-(2-(oxazol-2-yl)-5-(4-(4-((propan-2-yl)oxy)benzenesulfonyl(piperazin-1-yl)phenoxy)acetic Acid

2. Bge 175

3. Bge-175

4. S-555739

2.3.2 Depositor-Supplied Synonyms

1. 932372-01-5

2. Asapiprant [inn]

3. Bge-175

4. B2lw71crgl

5. S-555739

6. Bge175

7. 2-(5-(4-((4-isopropoxyphenyl)sulfonyl)piperazin-1-yl)-2-(oxazol-2-yl)phenoxy)acetic Acid

8. 2-(2-(oxazol-2-yl)-5-(4-(4-((propan-2-yl)oxy)benzenesulfonyl(piperazin-1-yl)phenoxy)acetic Acid

9. Acetic Acid, 2-(5-(4-((4-(1-methylethoxy)phenyl)sulfonyl)-1-piperazinyl)-2-(2-oxazolyl)phenoxy)-

10. Unii-b2lw71crgl

11. Bge175 [who-dd]

12. Schembl1106973

13. Chembl3545043

14. Gtpl11951

15. Bcp30346

16. Ex-a2993

17. Zb1516

18. Akos037515672

19. Cs-8174

20. Sb19848

21. Example Ii-74 [us8153793b2]

22. 2-[2-(1,3-oxazol-2-yl)-5-[4-(4-propan-2-yloxyphenyl)sulfonylpiperazin-1-yl]phenoxy]acetic Acid

23. Ac-36280

24. Bs-17884

25. Hy-16763

26. A16983

27. D80655

28. S-555739; Cs-2811

29. Q27274281

30. S-555739; S 555739; S555739

2.4 Create Date

2012-08-20

3 Chemical and Physical Properties

Molecular Formula	C₂₄H₂₇N₃O₇S
Molecular Weight	501.6 g/mol
XLogP3	3.1
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	9
Exact Mass	501.15697138 g/mol
Monoisotopic Mass	501.15697138 g/mol
Topological Polar Surface Area	131 Å²
Heavy Atom Count	35
Formal Charge	0
Complexity	789
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1